# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹12,019 Cr** Q2 (+8% YoY) · **₹23,000+ Cr** H1 (+12% YoY) * **EBITDA:** **₹2,205 Cr** Q2 (+40% YoY) · **₹3,500+ Cr** H1 (+29% YoY) * **EBITDA Margin:** **18.3%** Q2 (+410 bps) · **22.7%** Segment Peak (+270 bps) * **PATMI:** **₹553 Cr** Q2 (vs ₹447 Cr loss) · **₹465 Cr** H1 (vs ₹827 Cr loss) * **Net Debt:** **₹23,802 Cr** ($2.7B) as of Sept 2025 (–₹3,729 Cr YoY) * **Leverage Ratios:** **2.7x** Net Debt/EBITDA (vs 5.4x) · **0.6x** Net Debt/Equity (vs 0.9x) ## B. Revenue & Profitability Synthesis * **Volume-Led Recovery:** Robust top-line growth was primarily fueled by strong volumes in North America and Latin America, successfully offsetting global pricing pressures. * **Operational Turnaround:** Significant bottom-line swing driven by lower input costs, improved capacity utilization, and a shift toward higher-margin differentiated and biological products. * **Efficiency Gains:** Margin expansion was supported by a **₹140 Cr** reduction in net exchange losses and a sharp narrowing of losses from associates and JVs. * **External Headwinds:** Managed U.S. tariff impacts via strategic inventory positioning, limiting the EBITDA hit to approximately **$3 million**. ## C. Balance Sheet Deleveraging * **Aggressive Debt Reduction:** Net debt fell by over **$600 million** YoY; management is targeting a further reduction in the net leverage ratio to **1.6x–1.8x** by fiscal year-end. * **Capital Infusion:** Successfully raised **₹1,685 Cr** through the final call of a rights issue, bolstering the liquidity cushion for upcoming obligations. * **Interest Savings:** Net finance costs dropped significantly due to a **$250 million** debt prepayment and a **125 bps** decline in SOFR-linked rates following credit outlook upgrades. * **Working Capital Discipline:** Cash cycle improved by **5 days** YoY to 118 days, despite seasonal inventory builds for the second half of the year. ## D. Cash Flow & Liquidity * **H2 Cash Release:** Management anticipates a massive cash inflow of **$900 million to $1.1 billion** in the second half, mirroring historical performance trends. * **Liquidity Buffer:** Entered Q3 with **$550 million** in cash and **$1.7 billion** in unutilized credit lines, providing high coverage for the immediate **$500 million** debt maturity. * **Credit Trajectory:** Outlook upgrades to 'Stable' by Fitch, S&P, and Moody’s signal a path toward regaining Investment Grade status through sustained capital productivity. --- # 2. Operating Segments ## A. Key Figures * **UPL Corp Revenue:** **+12%** YoY * **Advanta Seeds:** **+26%** Revenue Growth · **+57%** EBITDA Growth · **+14%** Volume * **H1 Group Performance:** **+5%** Revenue Growth · **>₹9,000 Cr** Contribution · **+400 bps** Margin Improvement * **Regional Revenue Growth:** **+79%** North America · **+10%** Latin America · **+12%** Africa & APAC · **-1%** Europe * **Super Specialty Chemicals (SSC):** **+18%** Revenue Growth · **+24%** EBITDA Growth ## B. UPL Corp & India Crop Protection * **Volume-Led Recovery:** Global crop protection growth was primarily fueled by robust volume gains, particularly in herbicides and fungicides across major geographies. * **Regional Divergence:** North American performance surged on high demand for post-patent herbicides, while India (UPL SAS) faced a **10% revenue decline** due to weather-related impacts on herbicide volumes. * **Margin Resilience:** Despite top-line pressure in India, UPL SAS expanded EBITDA margins to **20%** through a superior product mix and successful new launches. * **Portfolio Mix:** Management projects a full-year revenue split of **60% post-patent** and **40% differentiated and sustainable (D&S)**, with a shift to annual disclosure for these segments. ## C. Advanta Seeds Growth * **Market Expansion:** Significant double-digit revenue and EBITDA growth were driven by volume expansion in India, Indonesia, and Latin American markets. * **FY26 Outlook:** The platform maintains a strong trajectory characterized by volume-led growth and EBITDA accretion. * **Strategic Moat:** Future scaling is supported by strengthening germplasm via in-house R&D and strategic acquisitions to enhance go-to-market capabilities. ## D. SUPERFORM & Specialty Chemicals * **Non-Agchem Pivot:** The Super Specialty business grew robustly due to higher contract manufacturing, increasing its revenue share to **25%** of the platform. * **Medium-Term Target:** Management expects the non-agchem share to reach **30% to 35%** within **24 to 36 months**, acting as a primary driver for continuous margin expansion. * **Operational Structure:** The segment is characterized as **working capital neutral** with fixed capital estimated between **$500 million and $600 million**; internal sales to anchor customers account for **75%** of revenue. ## E. Regional Market Dynamics * **Latin American Momentum:** Growth was supported by Brazilian fungicides and a recovery in Argentina, though pricing pressure persists specifically for the **Sperto®** brand. * **European Normalization:** Revenues remained nearly flat as fungicide sales stabilized following a previous wet season, despite growth in core markets like Germany and France. * **Tariff Exposure:** Management noted that while the Crop business is materially sensitive to --- # 3. Product & Supply Chain ## A. Key Figures * **Working Capital Cycle:** **124 days** Inventory · **151 days** Payables · **146 days** Receivables * **Factoring:** **$553 million** Non-recourse (Flat YoY) * **New Product Revenue:** **>$130 million** Current year guidance * **Intellectual Property:** **3,000+ patents** secured · **65-70 year** germplasm history ## B. Portfolio & Innovation * **Strategic Pivot to D&S:** Management is aggressively shifting toward the Differentiated and Sustainable (D&S) segment, with **80% of new launches** concentrated in this high-value category to drive margin expansion. * **Competitive Moat in Seeds:** The Advanta brand leverages deep genomics and proprietary germplasm to create environment-specific combinations, protected by a long-term R&D pipeline with an **8-10 year** development cycle. * **Specialty Diversification:** The Super Specialty arm is scaling contract manufacturing across pharma and industrial sectors, utilizing **five core technology platforms** including phosgenation and phosphorus chemistries. ## C. Inventory & Costing * **Inventory Refresh Completed:** The liquidation of high-cost stock (previously **100 days** of coverage) is finished; the company is now competing with fresh inventory at current market-low costs. * **Working Capital Normalization:** While current cycles have lengthened, management is targeting a sustainable long-term window of **65 to 70 days**, anticipating seasonal cash absorption in the Americas. * **India Market Calibration:** To prevent a repeat of last year’s abnormal sales returns, the company has tightened inventory placement; early-season herbicide returns are already fully accounted for in Q2. ## D. Manufacturing & Supply Chain * **Operational Efficiency:** Supply chain optimization is focused on high-volume plant utilization to maximize fixed-cost absorption while maintaining lean inventory levels. * **Tariff Mitigation Strategies:** To counter import duties, UPL is increasing **onshore U.S. manufacturing** and utilizing bonded warehouses to delay duty triggers in anticipation of potential rate changes. --- # 4. Strategic Initiatives ## A. Key Figures * **Annual Organic Capex:** **$200M - $225M** Projected for current fiscal * **Tangible Asset Investment:** **$140M - $150M** Annual spend to drive growth * **Capex Allocation:** **50%** Tangible assets · **50%** Intangible assets (Product registrations) ## B. Corporate Realignment & Leadership * **Strategic Pivot:** Group CFO Bikash Prasad is implementing an **"outside-in"** performance evaluation framework to better align reporting with investor and analyst expectations. * **Platform Integration:** Completed the merger of the **DECCO post-harvest business** into Advanta to capture cross-market synergies in infrastructure and digitization. * **Executive Transitions:** Appointed **Ravi Cherukuri** as CEO of UPL SAS (effective Oct 2025), while former head Ashish Dobhal elevates to Global Sales Head for UPL Corp. ## C. Shareholder Value Unlocking * **Liquidity Events:** Management continues to evaluate restructuring and fundraising options, including a potential **IPO for the Advanta platform**, though specific timelines remain undisclosed. ## D. Capital Allocation * **Investment Discipline:** Total organic expenditure is maintained at a steady range, with a heavy focus on **product registrations** to secure long-term market access. * **Growth Funding:** Sustained investment in tangible assets supports the company's broader scaling objectives and operational footprint. --- # 5. Market & Competitive Position ## A. Key Figures * **Brazil Order Book:** **~20%** increase YoY * **Market Volume Growth:** **Low single-digit** global industry average * **Commodity Pricing:** **~10%** increase in soybean prices (CBOT) ## B. Volume & Pricing * **Pricing Stabilization:** Global product prices have largely leveled off, though high-value branded insecticides face pressure from generic and clone entries in Brazil. * **Tariff Pass-Through:** Pricing for the new crop year has been adjusted on an active-by-active basis to account for **additional tariff costs**, impacting farmer input expenses. * **Competitive Momentum:** Management is leveraging a broad portfolio to maintain momentum in a highly competitive global environment characterized by fluid dynamics from Chinese and Indian imports. ## C. Market Share & Demand Trends * **Industry Outperformance:** Significant growth in the Brazil order book suggests substantial market share gains against a backdrop of sluggish industry volume growth. * **Shift to Value:** Weakening farm economics are driving a notable shift toward the "value segment," with growers prioritizing high-quality, low-cost post-patent products. * **Inventory Normalization:** Global channel inventories have returned to normal levels, though low row crop prices continue to create liquidity stress for retailers in Latin America. ## D. Customer Liquidity & Supply Chain * **Improved Grower Sentiment:** Brazilian farmer liquidity remains solid as high prior-season volumes and recent double-digit gains in soybean prices offset lower commodity benchmarks. * **Supply Chain Stability:** High supplier comfort levels and strong operational performance allow the company to sustain current supply payment terms. * **Operational Excellence:** Market share expansion and margin growth are being supported by superior inventory and supply chain management relative to peers. --- # 6. Risks & Agricultural Factors ## A. Key Figures * **Expected Credit Loss (ECL):** **$9M** Q2 (vs. $21M Q1) · **$30M** H1 (+$7M YoY) **B. S. Import Tariffs:** **50%** current rate (vs. 10% in April) ## B. Tariff & Macro Risks * **Erosion of Competitive Advantage:** Recent tariff hikes on Indian imports to **50%** have eliminated the previous **20%** cost advantage held over Chinese competitors. * **Resilience Amid Volatility:** Management maintains that current trade barriers will not materially alter year-end financial outcomes due to supply chain optimizations and strategic partnerships. * **Macro Headwinds:** Performance faces pressure from geopolitical uncertainty and farm income stress caused by low commodity prices, partially offset by lower finance costs from **reduced SOFR rates**. * **Liquidity Focus:** While current leverage is comfortable, **Q4** is identified as the critical window for working capital management and cash flow delivery. ## C. Credit & ECL Risks * **Regional Credit Stress:** Total credit losses rose in the first half, with recent quarterly impacts primarily concentrated in the **Latin American** market. * **Expense Discipline:** Management is utilizing disciplined SG&A controls to mitigate the bottom-line impact of rising global credit losses. ## D. Weather & Seasonal Risks * **Favorable Brazilian Outlook:** Unusually wet early spring conditions in Brazil have created optimal soil moisture for soybeans and cotton. * **Product Demand Tailwinds:** Positive planting conditions are expected to catalyze robust demand for high-margin crop protection categories, including herbicides, insecticides, and fungicides. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **4% to 8%** FY26 projected range * **EBITDA Growth Guidance:** **12% to 16%** FY26 upgraded range (from 10-14%) * **New Product Revenue:** **>$130M** projected target for FY26 ## B. Upgraded FY26 Targets * **Guidance Revision:** Management raised full-year expectations for both top-line and bottom-line performance following a robust first half. * **Product Launch Momentum:** New product revenue is tracking to exceed initial targets, bolstered by significant traction in **Latin America** and a deepening pipeline. ## C. H2 Growth Projections * **Volume-Led Expansion:** Growth in the latter half of the fiscal year is anticipated to be almost entirely volume-driven, as pricing remains flat or faces a marginal **1%** contraction in Q3. * **Tariff Headwinds:** Results will face pressure from elevated